The Potential Role of sRAGE, KL-6, and SP-D as Prognostic Factors in Children With COVID-19

COVID-19 causes a wide spectrum of clinical illness, from upper respiratory symptoms to severe respiratory failure and death. Several plasma biomarkers -such as IL-6, C-reactive protein (CRP), D-dimer, the neutrophil-to-lymphocyte ratio, and ferritin, among others- have been studied as markers of disease severity and prognosis. Besides, as alveolar damage biomarkers such as Surfactant protein D (SP-D), Krebs von den Lungen-6 (KL-6), and soluble Receptor for Advanced Glycation end products (sRAGE) can be used in lung diseases as well as COVID-19 pneumonia. The investigators hypothesized that serum SP-D, KL-6 and sRAGE levels increases in the setting of COVID-19 pneumonia. In this prospective study the investigators aimed to determine the clinical value of serum KL-6, SP-D and sRAGE levels as a prognostic marker in children with COVID-19 patients. In the literature review, it has been determined that there is no study conducted or published in pediatric patients for this purpose, and it is aimed that our study will be a pioneer study on this subject.

Inclusion Criteria:Between 1 month-18 years oldSARS-CoV-2 PCR positiveNot having a chronic disease (cystic fibrosis, etc.)Volunteering to participate in the studyHealty ControlExclusion Criteria:Having a chronic diseasePatients who could not be diagnosed with SARS-CoV-2 infection by laboratory and/or radiological examinationsNot volunteering to participate in the stud